Volume 27, Number 11—November 2021
Research Letter
Online Registry of COVID-19–Associated Mucormycosis Cases, India, 2021
Table
Clinical characteristics of patients in an online registry of coronavirus disease–associated mucormycosis, India, 2021*
Characteristic | No. (%) |
---|---|
Total |
65 (100) |
Sex | |
M | 48 (74) |
F |
17 (26) |
Underlying conditions | |
Diabetes mellitus | 52 (80) |
Hypertension | 13 (20) |
Chronic corticosteroid use | 2 (3) |
Asthma/COPD |
1 (1.5) |
Hospitalized† | 54 (84) |
Intensive care unit‡ | 15 (28) |
Required surgical intervention |
26 (40) |
Site of infection | |
Sinus | 60 (92) |
Eye | 34 (52) |
Cerebral | 5 (7.7) |
Gastrointestinal | 5 (7.7) |
Skin | 1 (1.5) |
Pulmonary |
0 |
Treatment | |
Steroids | 53 (82) |
Methylprednisolone | 32 (49) |
Dexamethasone | 18 (28) |
Prednisone | 5 (8) |
Budesonide | 6 (9) |
Steroids >10 d§ | 28 (61) |
Antifungal medication | |
Posaconazole | 43 (66) |
Isavuconazole | 3 (5) |
Amphotericin B | 60 (92) |
Liposomal | 54 (83) |
Deoxycholate | 14 (22) |
Lipid complex | 8 (12) |
Antiviral medication | |
Remdesivir | 31 (48) |
Favipravir | 18 (28) |
Zinc supplementation | 36 (55) |
Other antimicrobial chemotherapy | |
Doxycycline | 30 (46) |
Azithromycin | 25 (38) |
Ivermectin |
25 (38) |
No. vaccine doses | |
0 | 56 (86) |
1 | 7 (11) |
2 | 2 (3) |
*Totals might exceed 100% when >1 category applies. COPD, chronic obstructive pulmonary disease. †Data available for 64 patients. ‡Data available for 54 patients. §Data available for 46 patients.